1. Home
  2. CFND vs RLYB Comparison

CFND vs RLYB Comparison

Compare CFND & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CFND

C1 Fund Inc.

N/A

Current Price

$3.85

Market Cap

27.4M

Sector

N/A

ML Signal

N/A

Logo Rallybio Corporation

RLYB

Rallybio Corporation

HOLD

Current Price

$10.83

Market Cap

28.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CFND
RLYB
Founded
N/A
2018
Country
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.4M
28.7M
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
CFND
RLYB
Price
$3.85
$10.83
Analyst Decision
Hold
Analyst Count
0
2
Target Price
N/A
N/A
AVG Volume (30 Days)
35.2K
227.3K
Earning Date
N/A
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
27.72
EPS
N/A
N/A
Revenue
N/A
$600,000.00
Revenue This Year
N/A
$17.61
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.68
$0.22
52 Week High
$9.67
$11.49

Technical Indicators

Market Signals
Indicator
CFND
RLYB
Relative Strength Index (RSI) 38.53 91.28
Support Level $3.82 $0.48
Resistance Level $4.08 N/A
Average True Range (ATR) 0.15 0.87
MACD 0.02 0.47
Stochastic Oscillator 37.48 91.30

Price Performance

Historical Comparison
CFND
RLYB

About CFND C1 Fund Inc.

C1 Fund Inc is a non-diversified, closed-end management investment company designed to give investors access to the private digital asset ecosystem. Its investment objective is to maximize its portfolio's total return. The fund targets a handpicked portfolio of the late-stage private companies driving the future of digital asset services and technology. It offers early access to the next generation of category-defining companies and aims to bridge the gap between public and private markets and give investors access to the private companies with the safeguards of a NYSE listed fund that is regulated and liquid.

About RLYB Rallybio Corporation

Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

Share on Social Networks: